Biocept Inc logo

Biocept Inc

$ 0.90 +0.0301 (+3.46%) 04:00 PM EST
P/E:
At Loss
P/B:
0.40
Market Cap:
$ 16.98M
Enterprise V:
$ -554.00K
Volume:
65.57K
Avg Vol (2M):
71.86K
Also Trade In:
Volume:
65.57K
Market Cap $:
16.98M
PE Ratio:
At Loss
Avg Vol (2-Month):
71.86K
Enterprise Value $:
-554.00K
PB Ratio:
0.40
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Name Current Vs Industry Vs History
Cash-To-Debt 2.24
Equity-to-Asset 0.6
Debt-to-Equity 0.33
Debt-to-EBITDA -2.43
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.47
Distress
Grey
Safe
Beneish M-Score -3.23
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.6
9-Day RSI 49.44
14-Day RSI 44.37
6-1 Month Momentum % -52.89
12-1 Month Momentum % -74.7

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.38
Quick Ratio 3.15
Cash Ratio 1.96
Days Inventory 28.09
Days Sales Outstanding 87.28
Days Payable 64.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -231.4

Financials (Next Earnings Date:2022-11-15 Est.)

BIOC's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BIOC

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 63.438
EPS (TTM) ($) -0.52
Beta 0.58
Volatility % 51.52
14-Day RSI 44.37
14-Day ATR ($) 0.070647
20-Day SMA ($) 0.901072
12-1 Month Momentum % -74.7
52-Week Range ($) 0.717 - 4.3955
Shares Outstanding (Mil) 16.92

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biocept Inc Filings

Document Form Filing Date
No Filing Data

Biocept Inc Analysis

Share your research

Headlines

See More
No news.